Literature DB >> 15289724

Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases.

Régis Peffault de Latour1, Gaëtan Des Guetz, Valérie Laurence, Thao Palangié, Jean-Yves Pierga, Véronique Diéras, Michel Jouve, Jean-Marc Extra, Pierre Pouillart, Didier Decaudin.   

Abstract

The aim of this study was to define the characteristics of patients with idiopathic thrombocytopenic purpura (ITP) and breast cancer and discuss the relationship between these two diseases. Ten patients treated for breast cancer and presenting with ITP were screened for this study. The diagnosis of breast cancer was confirmed by biopsy or surgical sample. The diagnosis of ITP was defined by 1) platelet count less than 140.10(9)/l with normal or increased number of megakaryocytes on bone marrow aspirate, 2) after exclusion of thrombocytopenia-induced medication or disorders, and 3) absence of splenomegaly. ITP was diagnosed before breast cancer in three cases, concomitantly in three, and after the diagnosis of breast cancer in four cases. Platelet count and breast cancer showed an independent course in seven cases, and appeared to be correlated in the other three patients. No correlation was found between the development of ITP and tumor characteristics. In contrast, the median platelet count was 15.10(9)/l (range 3-26) for the 3 patients with a correlation between the course of ITP and breast cancer evolution and 70.10(9)/l (range 20-90) for the other cases (p = 0.05, Mann-Whitney U test). Breast cancers are associated with ITP, with a parallel course of the two diseases in one third of cases. This may suggest tumor-induced immunologic thrombocytopenia.

Entities:  

Mesh:

Year:  2004        PMID: 15289724     DOI: 10.1097/01.coc.0000071461.61445.9a

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  8 in total

1.  Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura.

Authors:  Kimio Wakana; Toshiharu Yasugi; Yurie Nako; Tomomi Nei; Yoshikazu Ozaki; Katsumi Mizutani
Journal:  Int J Clin Oncol       Date:  2010-12-04       Impact factor: 3.402

Review 2.  Platelets: an outlook from biology through evidence-based achievements in critical care.

Authors:  Rubens C Costa-Filho; Fernando A Bozza
Journal:  Ann Transl Med       Date:  2017-11

3.  Idiopathic thrombocytopenic purpura in women with breast cancer.

Authors:  Mozhgan Alam Samimi; Nooshin Mirkheshti; Mitra Heidarpour; Mozhgan Abdollahi
Journal:  J Res Med Sci       Date:  2010-11       Impact factor: 1.852

4.  Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia.

Authors:  Roberto Stasi; Sergio Amadori; John Osborn; Adrian C Newland; Drew Provan
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

5.  Metastatic Breast Cancer with Extensive Osseous Metastasis Presenting with Symptomatic Immune Thrombocytopenic Purpura and Anemia: A Case Report and Review of the Literature.

Authors:  Jiaxin Niu; Teresa Goldin; Maurie Markman; Madappa N Kundranda
Journal:  Case Rep Oncol       Date:  2015-06-05

6.  Drug-induced immune thrombocytopenic purpura secondary to sunitinib.

Authors:  M Trinkaus; M Trudeau; J Callum
Journal:  Curr Oncol       Date:  2008-06       Impact factor: 3.677

7.  Idiopathic thrombocytopenic purpura after mastectomy and axillary lymph node dissection.

Authors:  Wil L Santivasi; Meghan M Routt; Alicia M Terando
Journal:  Case Rep Surg       Date:  2014-03-06

Review 8.  A Review on Secondary Immune Thrombocytopenia in Malaysia.

Authors:  Muhamad Aidil Zahidin; Noor Haslina Mohd Noor; Muhammad Farid Johan; Abu Dzarr Abdullah; Zefarina Zulkafli; Hisham Atan Edinur
Journal:  Healthcare (Basel)       Date:  2021-12-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.